Aurobindo Pharma acquires 80% stake in Tergene Biotech

01 Mar 2025 Evaluate

Aurobindo Pharma has completed the acquisition of entire 80% of the equity share capital of Tergene Biotech, a step-down subsidiary of the Tergene and also a joint venture company, held by Auro Vaccines, a wholly owned stepdown subsidiary of the Aurobindo Pharma. The purchase consideration is of Rs 10.76 crore. Post this transaction, Tergene has become a direct subsidiary of the company.

Earlier on February 6, 2025, the company’s board had approved to purchase entire 80% of the equity share capital of Tergene Biotech. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1171.40 9.55 (0.82%)
10-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.25
Dr. Reddys Lab 1251.10
Cipla 1489.15
Zydus Lifesciences 923.70
Lupin 2055.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×